A
Andrea S. Foulkes
Researcher at Harvard University
Publications - 108
Citations - 3806
Andrea S. Foulkes is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Viral load. The author has an hindex of 28, co-authored 94 publications receiving 2881 citations. Previous affiliations of Andrea S. Foulkes include University of Pennsylvania & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
John H. Stone,Matthew J. Frigault,Naomi Serling-Boyd,Ana D. Fernandes,Liam Harvey,Andrea S. Foulkes,Nora Horick,Brian C. Healy,Ruta Shah,Ana Maria Bensaci,Ann E. Woolley,Sarah Nikiforow,Nina Lin,Manish Sagar,Harry M Schrager,David S. Huckins,Matthew Axelrod,Michael D. Pincus,Jorge Fleisher,Chana A. Sacks,Michael Dougan,Crystal M. North,Yuan Di C. Halvorsen,Tara K. Thurber,Zeina Dagher,Allison K. Scherer,Rachel Wallwork,Arthur Y. Kim,Sara R. Schoenfeld,Pritha Sen,Tomas G. Neilan,Cory A. Perugino,Sebastian Unizony,Deborah S. Collier,Mark Matza,Janeth Yinh,Kathryn Bowman,Eric A. Meyerowitz,Amna Zafar,Zsofia D. Drobni,Marcy B. Bolster,Minna J. Kohler,Kristin M. D’Silva,Jonathan Dau,Megan Lockwood,Caroline Cubbison,Brittany Weber,Michael K. Mansour +47 more
TL;DR: Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19, and some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide.
Journal ArticleDOI
Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration
Livio Azzoni,Andrea S. Foulkes,Emmanouil Papasavvas,Angela M. Mexas,Kenneth Lynn,Kenneth Lynn,Karam Mounzer,Pablo Tebas,Jeffrey M. Jacobson,Ian Frank,Michael P. Busch,Steven G. Deeks,Mary Carrington,Una O'Doherty,Jay R. Kostman,Luis J. Montaner +15 more
TL;DR: In the absence of antiretroviral therapy (ART), the results of several clinical trials support a predominantly antiviral activity (i.e., approximately 0.5 log decrease in plasma viral load) when interferon alfa is administered to HIV-1-infected persons.
1 replication and decreased cell-associated HIV DNA integration
Livio Azzoni,Andrea S. Foulkes,Emmanouil Papasavvas,Angela M. Mexas,Kenneth Lynn,Karam Mounzer,Pablo Tebas,Jeffrey M. Jacobson,Michael P. Busch,Steven G. Deeks,Mary Carrington,Jay R. Kostman,Luis J. Montaner +12 more
TL;DR: Peg-interferon alfa-2a immunotherapy resulted in control of HIV replication and decreased HIV-1 integration, supporting a role for immunomediated approaches in HIV suppression and/or eradication.
Journal ArticleDOI
Circulating Monocytes in HIV-1-Infected Viremic Subjects Exhibit an Antiapoptosis Gene Signature and Virus- and Host-Mediated Apoptosis Resistance
Malavika S. Giri,Michael Nebozyhn,Andrea D. Raymond,Bethsebah Gekonge,Aidan Hancock,Shenoa Creer,Calen Nicols,Malik Yousef,Andrea S. Foulkes,Karam Mounzer,Jane Shull,Guido Silvestri,Jay Kostman,Ronald G. Collman,Louise C. Showe,Luis J. Montaner +15 more
TL;DR: It is shown that monocyte CCR5 binding by HIV-1 virus or agonist chemokines serves as independent viral and host modulators resulting in increased monocyte apoptosis resistance in vitro.
Journal ArticleDOI
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.
Andrea S. Foulkes,David A. Wohl,Ian Frank,Elaine Puleo,Stephanie Restine,Megan L. Wolfe,Michael P. Dubé,Pablo Tebas,Muredach P. Reilly +8 more
TL;DR: In the first pharmacogenetic study of its kind in HIV-1 disease, race/ethnic-specific differences in plasma lipid levels on ART are found as well as differences in the influence of the apoC-III gene on the development of PI-related hypertriglyceridemia.